myelopathy/tropical spastic paraparesis. Quantitative reverse transcription PCR analysis revealed that EM2487 selectively suppressed HTLV-I mRNA synthesis in MT-2 cells in a dosedependent fashion. However, the compound did not inhibit endogenous Tax-induced HTLV-I long terminal repeat-driven reporter gene expression. Furthermore, intracellular Tax accumulation was not suppressed in MT-2 cells exposed to EM2487. These results suggest that the inhibition occurred at the viral transcription level, but it cannot be attributed to the inhibition of the Tax function.
Human T-lymphotropic virus type I (HTLV-I) is the causative agent of adult T-cell leukaemia (ATL) (Uchiyama et al., 1977) and HTLV-I-associated myelopathy/tropical spastic paraparesis (HAM/TSP) (Gessain et al., 1985; Osame et al., 1986) . These diseases are generally manifested 40 to 60 years after HTLV-I infection in the newborn period (Uchiyama et al., 1977) . However, little is known about the pathogenic process from latent infection to the development of the diseases. In addition, there are no effective treatment regimens for HTLV-I infection. Considering the limitation of corticosteroids and its combination chemotherapy, discovery of specific anti-HTLV-I agents is highly desirable (Vernant et al., 1987; Lofters et al., 1987) .
The load of provirus is generally high in peripheral blood mononuclear cells (PBMCs) of HAM/TSP patients, and the risk of this disease is positively correlated with the magnitude of the proviral load in PBMCs (Nagai et al., 1998) . Since several lines of evidence suggest that the replication of HTLV-I appears to influence on the development of HAM/TSP, direct inhibition of a crucial step in the viral replication cycle could reduce the proviral load and protect HTLV-I carriers against the development of the disease (Kira et al., 1992; Bieganowska et al., 1999; Taylor et al., 1999) .
HTLV-I has two regulatory genes, such as tax and rex, which control the viral gene expression and are indispensable for efficient viral replication (Cann & Chen, 1996; Franchini, 1995) . Tax activates transcription of the viral genome, whereas rex modulates the processing of the viral mRNA and expressing unspliced and singly spliced forms of the mRNA (Chen et al., 1985; Felber et al., 1985; Inoue et al., 1987; Hidaka et al., 1988) . Since tax and rex are essential for viral replication, these molecules are considered a suitable target for inhibition of HTLV-I. We have recently reported that EM2487, a novel small-molecule substance produced by a Streptomyces species, selectively inhibits HIV-1 replication through the inhibition of viral transcription with an unidentified mechanism . In this study, we have found that EM2487 is also a selective inhibitor of HTLV-I replication through the inhibition of viral transcription, though it cannot be attributed to the inhibition of tax function. (Figure 1 ) was provided by Esai Co., Tsukuba, Japan. The purity of the final preparation was more than 99.9% (data not shown). The HIV-1 reverse transcriptase inhibitor zidovudine (AZT) was purchased from Sigma (St. Louis, Mo., USA). The HIV-1 protease inhibitor indinavir (IDV) was provided by Takeda Chemical Industries (Osaka, Japan). All compounds were dissolved in dimethyl sulphoxide (DMSO) at 10 mM or higher concentrations to exclude any antiviral or cytotoxic effect of DMSO and stored -20°C until use.
Cells
MT-2, MT-4, and PBMCs were used in the antiviral assays. MT-4 and MT-2 cells are T-lymphoblastoid cell lines persistently infected with HTLV-I (Miyoshi et al., 1981 (Miyoshi et al., , 1982 . These cell lines were cultured in RPMI 1640 medium supplemented with 10% heat inactivated fetal bovine serum (FBS), 100 U/ml penicillin G, and 100 µg/ml streptomycin (culture medium). HTLV-I-infected PBMCs were donated under informed consent from patients with a clinical diagnosis of HAM/TSP. PBMCs were isolated from heparinized blood with Ficoll-Paque Plus (Pharmacia, Uppsala, Sweden) and washed three times with phosphate-buffered saline (PBS). PBMCs were cultured in RPMI 1640 medium supplemented with 20% FBS and antibiotics, and 100 U/ml interleukin-2 (Takeda Chemical Industries). The uninfected cell line Jurkat was also used in the experiments.
Antiviral assays
The activity of the compounds against persistent HTLV-I infection was based on the inhibition of HTLV-I p19 antigen production in MT-2 and MT-4 cells. MT-2 and MT-4 cells (10 5 cells/ml) were cultured in the presence of various concentrations of test compounds. After a 3-day incubation at 37°C, the culture supernatants were collected and examined for their p19 antigen levels with a sandwich enzyme-linked immunosorbent assay (ELISA) kit (Cellular Products, Buffalo, NY, USA). The cytotoxicity of the compounds was determined in parallel with the antiviral activity by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) method (Pauwels et al., 1988) . The anti-HTLV-I activity of the compounds was also evaluated in PBMCs from HAM/TSP patients. The cells (2×10 5 to 1×10 6 cells/ml) were cultured in the presence of various concentrations of test compounds. After 6 days, the culture supernatants were collected and examined for their p19 antigen levels by ELISA. The number of viable cells was also determined by the MTT method.
Quantitative reverse transcription-polymerase chain reaction (RT-PCR)
MT-2 cells (2×10 5 cells/ml) were incubated in the absence or presence of EM2487 for 2 days. Total RNA was extracted from the cells with the RNA extraction kit RNAzol B™ (Tel-Test, Friendswood, Tex., USA). The extracted RNA was subjected to quantitative RT-PCR analysis to determine HTLV-I mRNA, using GeneAmp 5700 Sequence Detection System (Applied Biosystems, Foster City, Calif., USA). Takenouchi et al., 1999) . Non-specific inhibition of host cellular mRNA synthesis by EM2487 was determined with the Taqman glyceraldehydes-3-phophate dehydrogenase (GAPDH) Control Reagents kit (Applied Biosystems).
Plasmids
Four luciferase reporter plasmids, WT-Luc, LTR-Luc, dN55-Luc, and RSV-Luc, were used in the experiments. All of the plasmids were based on pGL2-Basic (Promega, Madison, Wis., USA). WT-Luc was constructed by ligation of the XbaI-XhoI fragment of WT/BL (Fujisawa et al., 1989) to NheI-XhoI-digested pGL2-Basic. WT-Luc contains five tandem repeats of the 21-bp enhancer and the HTLV-1 promoter. DN55-Luc was the enhancer-deleted control reporter. The long terminal repeat (LTR) sequences of HTLV-1 and Rous sarcoma virus (RSV) were placed at the upstream of luciferase gene, and the generated plasmids were referred as LTR-Luc and RSV-Luc, respectively.
Transfection and luciferase assays
MT-2 cells (2×10 6 cells) were transfected with 2 µg of different reporter plasmids, using diethylaminoethyl (DEAE)-dextran (Fujisawa et al., 1989) . After a 2-h incubation, the transfected cells were harvested and subcultured in the absence or presence of test compounds in a 96-well plate. After a 24-h incubation at 37°C, the cells were treated with 50 µl of luciferase reaction buffer containing cell lysis reagents and 50 µl of luciferin substrate in LucScreen TM System (Applied Biosystems). Luciferase activity was measured sequentially by MicroLumat Plus LB96V microplate luminometer with an injection unit (Berthold Technologies, Bad Wildbad, Germany). The number of viable cells was determined by the MTT method.
Results

Anti-HTLV-I activity in persistently infected cell lines
When EM2487 was examined for its inhibitory effect on HTLV-I replication in MT-2 cells, the compound could suppress HTLV-I p19 antigen production in a dosedependent fashion (Figure 3a) . The compound achieved 50% inhibition of antigen production in the culture supernatants at a concentration of about 4.0 µM. However, EM2487 did not significantly affect the proliferation and viability of MT-2 cells at this concentration, indicating that the inhibition was selective to HTLV-I replication. In contrast, AZT and IDV proved inactive against HTLV-I replication in MT-2 cells (Figures 3b and c) . The anti-HTLV-I activity of EM2487 was confirmed in MT-4 cells, another cell line persistently infected with HTLV-I. Table 1 summarizes the anti-HTLV-I activity and cytotoxicity of EM2487, AZT and IDV. The 50% effective concentrations (EC 50 s) of EM2487 were 3.6 and 1.2 µM, while its 50% cytotoxic concentrations (CC 50 s) were 30.6 and 5.7 µM in MT-2 and MT-4 cells, respectively. Consequently, the selectivity indices (SIs), based on the ratio of EC 50 to CC 50 , were 8.5 and 4.8 in MT-2 and MT-4 cells, respectively. Although these values were less than 10, they were statistically significant (Table 1) .
Anti-HTLV-I activity in peripheral blood mononuclear cells from HAM/TSP patients
In the next experiment, we examined whether EM2487 could inhibit HTLV-I replication in PBMCs obtained from two HAM/TSP patients. In vitro cultivation of Antiviral Chemistry & Chemotherapy 13:3 3 
patient PBMCs induces the production of p19 in the culture supernatants after several days. In fact, approximately 60 pg/ml p19 antigen was detected after 6 days of cultivation (data not shown). EM2487 dose-dependently reduced p19 antigen levels in the two PBMC samples (Figure 4 ). It reduced p19 antigen production by 30-50% of the control level at a concentration of 0.8 µM. However, it did not significantly affect the viability of PBMCs at concentrations up to 4 µM. The EC 50 s of EM2487 in the PBMCs from two patients were 0.3 and 1.4 µM, whereas its CC 50 s were 8.9 and 11.4 µM, respectively. The SIs were 29.7 for one patient and 8.1 for the other.
Inhibitory effect of EM2487 on HTLV-I transcription
Since EM2487 had been shown to interfere with HIV-1 transcription , the compound was also expected to act as an HTLV-I transcription inhibitor. Therefore, we examined whether EM2487 could prevent HTLV-1 mRNA synthesis in MT-2 cells. Quantitative RT-PCR analysis revealed that EM2487 selectively suppressed HTLV-I mRNA synthesis in a dose-dependent fashion ( Figure 5 ). However, it did not affect the host cellular mRNA synthesis at concentrations up to 20 µM, indicating that the inhibition of gene expression by EM2487 is selective to HTLV-I.
Effect on Tax-induced transactivation
To gain insight into mechanism of action, the inhibitory effect of EM2487 on endogenous Tax-induced transactivation was examined in MT-2 cells. Interestingly, EM2487 did not display significant inhibition of the HTLV-I LTRor the 21-bp enhancer-driven reporter gene expression even at a concentration of 20 µM (Figure 6 ). A similar result was also observed for the RSV LTR-mediated gene expression or the basal transcription (dN55-Luc). Furthermore, Western blot analysis with an anti-Tax monoclonal antibody (Tanaka et al., 1990) confirmed that HTLV-I p40 Tax expression was not affected by exposure to EM2487 in MT-2 cells (data not shown). These results indicate that the inhibition of HTLV-I replication occurs at a transcriptional level; nevertheless this is not due to the inhibition of Tax-induced transactivation or the inhibition of intracellular accumulation of Tax.
Discussion
By screening more than 75000 compounds in a Tatinduced HIV-1 LTR-driven reporter gene expression system, EM2487 was found as a potent and selective inhibitor of HIV-1 replication in acutely and chronically infected cells Takeuchi et al., 1999) . EM2487 was also active against simian immunodeficiency virus but inactive against HTLV-I in reporter gene assay systems (Baba , 1999) . HTLV-I is another pathogenic human retrovirus that shares many properties with HIV-1 beyond the general nature of retrovirus. In particular, HTLV-I and HIV-1 use similar strategies for the regulation of viral gene expression. However, while cell-free viral transmission occurs frequently in HIV-1 infection, HTLV-I is almost exclusively transmitted by cell-to-cell contact (Yoshida, 1987) . Although in vitro infection with a high amount of cell-free virions has been reported, an assay system with cell-free HTLV-I for evaluating antiviral agents has not been established yet (De Rossi et al., 1985) . Therefore, we attempted to evaluate the inhibitory effect of EM2487 on HTLV-I replication in persistently infected cells. EM2487 inhibited the expression of HTLV-I p19 antigen in MT-2 and MT-4 cells at non-toxic concentrations ( Figure 3 and Table 1 ). In addition, the compound could prevent unspliced and singly spliced HTLV-I mRNA expression in a dose-dependent fashion without affecting host-cellular mRNA expression (Figure 5 ), suggesting that the inhibition occurred at a level of viral transcriptional. It is assumed that known and unknown cellular factors are required for HTLV-I replication. For instance, cellular transcriptional factors, such as the CREB/ATF family proteins, as well as the HTLV-I Tax and Rex regulate HTLV-I transcription (Cann & Chen, 1996; Franchini, 1995) . Recently, we identified that the fluoroquinoline derivative K-37 was a selective inhibitor of HTLV-I replication in persistently infected cells (Wang et al., 2002) . Although EM2487 totally differs in chemical structure from K-37, they had a similar anti-HTLV-I activity in MT-2 and MT-4 cells and in PBMCs from HAM/TSP patients. Furthermore, both EM2487 and K-37 suppressed the HIV-1 Tat-induced transactivation. It is possible both compounds share the same cellular factor associated with Tat as their target (Baba et al., 1998 . However, as far as the anti-HTLV-I activity is concerned, the mechanism for the action of K-37 is attributed to the inhibition of endogenous HTLV-I Tax expression in persistently infected cells, whereas EM2487 did not show any inhibition of Tax-dependent reporter gene expression or endogenous Tax expression (Figure 6 and data not shown).
Both Tax and Tat are highly potent transactivators of viral gene expression, but their machinery and involvement of cellular factors seems totally different. Therefore, it would not be surprising that EM2487 is capable of inhibiting Tat but not Tax function. On the other hand, it cannot be excluded that EM2487 interacts with the same factor involved in HIV-1 and HTLV-I gene expression, in particular, a molecule that regulates the transport of viral mRNA. In fact, HTLV-I Rex and HIV-1 Rev are not homologous in structure, but they control the transport of unspliced and singly spliced viral mRNA in a similar way (Bogerd et al., 1995 (Bogerd et al., , 1998 . Further studies are in progress to clarify the target molecule of EM2487.
In conclusion, EM2487 appears to be a selective inhibitor of HTLV-I transcription in persistently infected cells. More importantly, the compound is effective in inhibiting viral expression in PBMCs from HAM/TSP patients. Therefore, our findings might have potential for the discovery of novel agents against HTLV-I replication and possibly for the therapy of HAM/TSP. To confirm the antiviral activity of EM2487 in acute infection, develop- ment of an assay system of acute infection with cell-free virions is in progress in our laboratory.
